WSSAAI 2024 Northwest Allergy Forum

Seattle, WA US
October 5, 2024 to October 6, 2024

The NWAF is an annual educational conference hosted on alternate years by the Washington and Oregon Societies of Allergy, Asthma and Immunology.  In 2024, the NWAF will be hosting by the WSSAAI.  The conference is attended by allergists, Fellows in Training, physicians in related specialties as well as Residents, Medical Students and Nurses. The 2-day program with both local and national speakers will cover disease states such as atopic dermatitis, JAK inhibitors, EGPA, chronic rhinosinusitis, asthma biologics and nasal congestion.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunology and the Washington State Society of Allergy, Asthma & Immunology (WSSAAI). The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 8 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 8 contact hours.

Commercial Support
No commercial support was received for this activity.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

At the conclusion of the conference, participants should be able to:
•    Summarize safety data and strategic use of immunomodulators for patients with AD during pregnancy/breastfeeding
•    Review practice gaps in clinical care and research in AD
•    Appreciate the value of endotyping with biomarkers and multi-omics scaling in the management of severe asthma
•    Be familiar with the concepts of advanced of MRI and CT imaging of airways in clinical practice to evaluate severe asthma
•    Choose the right biologic for the right patient with severe asthma and switch treatment appropriately
•    Appreciate the current international guidelines on the medical treatment of chronic rhinosinusitis.
•    Understand the rationale behind surgical procedures for chronic rhinosinusitis with and without nasal polyps.
•    Recognize the novel procedural in-office options for treating nasal airway obstruction.
•    Recognize signs and symptoms of post-nasal drainage.
•    Understand the risks and benefits of the various medical and procedural treatment options for significant post-nasal drainage. 
•    Discuss new and emerging topical and systemic medications in atopic dermatitis
•    Identify patient types that would be ideal candidates for these therapies
•    Review the efficacy of JAK inhibitors when compared to other systemic therapies
•    Discuss the safety of JAK inhibitors and contextualize this in an atopic dermatitis population
•    Apply best practices for risk mitigation and patient adherence
•    Identify the most effective medical treatments for CRSsNP, CRSwNP and AFRS.
•    Evaluate and select evolving therapeutic strategies
•    Review mechanisms, current biologics and effects
•    Evaluate current clinical data indicating suggesting possible remittive effects of biologics in asthma

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

NO COMMERICAL SUPPORT WAS RECEIVED FOR THIS ACTIVITY

Course summary
Available credit: 
  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
  • 8.00 CBRN
Course opens: 
10/05/2024
Course expires: 
12/31/2025
Event starts: 
10/05/2024 - 8:30am CDT
Event ends: 
10/06/2024 - 2:30pm CDT
Add to calendar: 
Rating: 
0

Northwest Allergy Forum |   October 5-6, 2024
Grand Hyatt, Seattle, WA | 721 Pine Street | Seattle, WA | (206) 774-6300

Saturday, October 5th

6:30am-7:50am    Exhibits | Registration | Coffee Break 

NWAF General Session 

7:50am-8:00am    Welcome & Introduction – Ted Song, DO, WSSAAI; Session Moderator – Leonard Altman, MD, WSSAAI

8:00am-9:00am     Complementary and Alternative Treatments for Atopic Dermatitis, Vivian Y. Shi, MD, FAAD 

9:00am-10:00am     “JAK of all trades, Master of Atopic Dermatitis?”, E. James Song, MD, FAAD

10:00am-10:30am    Coffee Break | Exhibits

10:30-11:30am     AD Treatment in Special Considerations, Vivian Y. Shi, MD, FAAD

11:30am-12:30pm    New and Emerging Topical and Systemic Medications in Atopic Dermatitis, E. James Song, MD, FAAD

12:30pm    Adjourn

12:30pm-1:30pm     WSSAAI/OSAAI State Society Lunch Meetings (Non-CME)

Sunday, October 6th  

7:00am-8:00am    Exhibits | Coffee Break 

NWAF General Session 

7:50am-8:00am    Welcome & Introduction, Session Moderator – Lahari Rampur, MD– Executive Director

8:00am-9:00am        Comprehensive Medical and Surgical Management of Chronic Rhinosinusitis Greg Davis, MD, MPH

9:00am-10:00am     Update on Mechanisms and Management of EGPA , Parameswaran Nair, MD, PhD

10:00am-10:30am     Coffee Break | Exhibits                      

10:30am-11:30am     Novel, Non-invasive In-Office Treatments for Nasal Congestion and Eustachian Tube Dysfunction, Greg Davis, MD, MPH

11:30am-12:30pm     The Concept of Remission in Severe Asthma, Parameswaran Nair, MD, PhD     

12:30pm        Adjourn 

Grand Hyatt Seattle
721 Pine Street
Seattle, WA 98101
United States

All relevant financial relationships with ineligible companies have been mitigated.

All relevant financial relationships with ineligible companies have been mitigated.

Greg E. Davis, MD, MPH – Speaker
Advisor: Medtronic, Neurent Medical, Optinose
Consultant: Aerin Medical, Medtronic, SpirAir
Researcher: Neurent Medical, SpirAir
Speaker: Aerin Medical

Parameswaran Nair, MD, PhD – Speaker
Consultant: Arrowhead
Grants: Genentech, Roche
Researcher: AstraZeneca, Sanofi
Speaker: AstraZeneca, GSK, Sanofi

Vivian Y. Shi, MD
Consultant: AbbVie, Almirall, Eli Lilly, Incyte, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, UCB

E. James Song, MD
Advisor:  Abbvie, Amgen, Arcutis, BMS, Boehringer-Ingelheim, Dermavant, Incyte, Eli Lilly, Janssen, SUN pharma, LEO, Novartis, Alphynn, Sanofi & Regeneron, Pfizer, APOGEE, Galderma, UCB
Consultant:  Abbvie, Amgen, Arcutis, BMS, Boehringer-Ingelheim, Dermavant, Incyte, Eli Lilly, Janssen, SUN pharma, LEO, Novartis, Alphynn, Sanofi & Regeneron, Pfizer, APOGEE, Galderma, UCB
Researcher:  Abbvie, Amgen, Arcutis, BMS, Incyte, Janssen, SUN pharma, LEO, Pfizer, APOGEE, DermBiont, Corevitas, TARGET
Speaker:  Abbvie, Amgen, Arcutis, BMS, Dermavant, Incyte, Eli Lilly, Janssen, SUN pharma, Sanofi & Regeneron, Pfizer, Galderma, UCB

T. Ted Song , DO – Planner & Moderator
Speaker:  AstraZeneca

The following have no relevant financial relationships with ineligible companies to disclose:

Leonard C. Altman, MD – Planner & Moderator
Lahari Rampur, MD – Planner & Moderator
Mark Tucker, MD – Planner 
Karol Anderson – Planner

Available Credit

  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
  • 8.00 CBRN
Please login or create an account to take this course.